The Right Drug or Trial for Every Patient. This is the OmniSeq Mission.
OmniSeq® was founded with one purpose in mind: To inform physicians and their patients of the most actionable tumor-profiling information possible. We know that, when we accomplish this goal, we’re enabling patients to benefit from personalized treatment that will help them fight their illness at a molecular level.
At Omniseq®, we advance personalized medicine by focusing solely on the improvement of patient outcomes.
This is Who We Are.
Founded in 2015, OmniSeq® is a commercial, CAP accredited, CLIA and New York State CLEP licensed clinical laboratory in Buffalo, New York. We utilize next generation sequencing (NGS) technologies through New York State CLEP approved comprehensive molecular profiling, as well as offer a wide variety of pharmaceutical services to assist in drug development.
This is Our Legacy.
Roswell Park Comprehensive Cancer Center in Buffalo, New York is a pioneer clinical research facility for advanced treatment of all forms of adult and pediatric cancer, and a Member of the National Comprehensive Cancer Network. Roswell Park Comprehensive Cancer Center’s Founder, Dr. Roswell Park, sought to cure cancer and advocated a close connection between laboratory and clinical research to speed up discovery, and Roswell Park Comprehensive Cancer Center was the first institution to focus exclusively on cancer research.
After more than a century, Roswell Park Comprehensive Cancer Center continues to be at the forefront of groundbreaking cancer research. The institute’s history includes initiating the first experiments in chemotherapy in 1904; becoming America’s first Comprehensive Cancer Center; and providing the source, RP11 (RP stands for Roswell Park), for much of the BAC clone library used in the Human Genome Project.
OmniSeq® emerged from the Roswell Park Comprehensive Cancer Center’s Center of Personalized Medicine, and the breakthrough research, scientific expertise, and commitment to improving patient care define what OmniSeq® is today.
Dr. Carl Morrison, Founder of OmniSeq® and Executive Director of the Center for Personalized Medicine at Roswell Park Comprehensive Cancer Center, first envisioned the role of more advanced bioinformatics in clinical decision support while working at Roswell Park.
OmniSeq Laboratory Team
Roger D. Klein, MD, JD, FACP
Chief Medical Officer
Shengle Zhang, MD
Sean Glenn, PhD
SVP, Laboratory Operations and Research Development
Assistant Laboratory Director
Chief Scientific Officer
OmniSeq Executive Team
Chief Executive Officer
SVP, Corporate Strategy and Business Development
Mary K. Nesline
SVP, Clinical Evidence Development
Paul DePietro, PhD
Executive Director, Knowledge Informatics
Executive Director, Payer and Client Relations
Daria Shanchuk, CPA, MBA
Executive Director, Regulatory Affairs and Quality Assurance
OmniSeq Board of Directors
Paul Billings, MD, Ph.D, FACP, FACGMP
Chief Medical Officer, Natera
Steven M. Anderson, PhD
Chief Scientific Officer, Covance
Sr VP, LabCorp
Marcia Eisenberg, PhD
Chief Scientific Officer and SVP, LabCorp
Mark Gardner, MBA
Senior Vice President, Corza Health
Kelvin P. Lee, MD
Director, Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Margot Schoenborn, Esq.
Chief Executive Officer, OmniSeq
R. Buford Sears